PHILLIPSBURG, N.J.--(BUSINESS WIRE)--June 8, 2006--Sentigen Holding Corp. (Nasdaq: SGHL - News) today announced the issuance of U.S. Patent No. 7,049,076 entitled “Method for Assaying Protein-Protein Interaction,” covering the core methods underlying the company’s Tango(TM) Assay System. The Tango Assay System was designed to allow the detection of virtually any protein-protein interaction in a cell with exceptional sensitivity and selectivity. While this issued patent includes claims for the use of the technology for any class of protein drug targets, the company is currently applying the Tango Assay System to accelerate the discovery and testing of new therapeutics that target G Protein-Coupled Receptors (GPCRs), widely believed to represent the most successful class of drug targets. The selectivity and sensitivity of the Tango technology should enable the de-orphaning of GPCRs using complex biological mixtures, such as tissue extracts.
